Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study identified histologic lesions and a defect in adhesion molecules causing hair loss in mice with the bal mutation, linked to a mutation in the desmoglein 3 gene.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This article reviews the medicinal significance of the Eclipta alba plant in India and its therapeutic properties, but reports no new clinical results.

This study found that autophagy is impaired in Birt-Hogg-Dubé syndrome-associated renal tumors and identified that the FLCN protein interacts with key autophagy components regulated by ULK1.

The BASP classification helps predict patient behavior and improve treatment for hair loss.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

This review highlights that Eclipta alba, or false daisy, shows promise for liver protection and hair care due to its antioxidant and tissue-protective properties, supporting its traditional Ayurvedic uses for treating liver disorders and promoting hair growth.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

This study investigated a patient with spinal and bulbar muscular atrophy who had 68 CAG repeats, revealing early onset and unique symptoms not previously documented in the condition.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this study of duku trees along the Batanghari River in Indonesia, researchers identified traits in mother trees that may help select for resistance to stem canker disease.

This case report describes the occurrence of juvenile diabetes mellitus with concurrent exocrine pancreatic insufficiency in a Thai Bangkaew dog, highlighting its successful management with insulin, pancreatic enzymes, and methylcobalamin.

This study found that the JAK1 rs310241 AG genotype is associated with a 4.6-fold increased risk of alopecia areata, whereas JAK2 polymorphisms showed no significant link, suggesting a potential genetic susceptibility factor warranting further research.

This case report highlights the successful treatment of alopecia areata universalis with Baricitinib, suggesting potential long-term effectiveness of janus kinase inhibitors for this autoimmune hair loss condition.

This research suggests that the barley protein RACB supports cell polarity functions rather than interfering with immunity, as it aids nucleus positioning during fungal attack rather than affecting early immune responses.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study found that baricitinib is effective for treating severe alopecia areata, with significant hair regrowth observed by the third month of therapy and continued improvement by month 12, while adverse events were mainly mild.

This article examines the Ayurvedic approach to treating polycystic ovarian syndrome with Basti therapy and discusses its potential for both lean and obese phenotypes, but provides no new clinical results.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

This review discusses the potential health benefits of Indian gooseberries, including blood glucose management and cardiovascular health, and highlights the need for additional research; no new clinical results are reported.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

Bardet-Biedl syndrome may include under-recognized skin problems related to its metabolic disturbances.

This abstract discusses Netherton Syndrome, a genetic disorder with a characteristic triad of symptoms caused by SPINK5 gene mutation, and reports no new clinical findings or treatment advances.

This review discusses the various medicinal properties attributed to the banana plant and reports no new clinical results; the authors suggest its potential in herbal medicine.

In this randomized controlled trial, the combination of Bhringaraja Taila Shiroabhyanga and Yastimadhuka Taila Nasya was found to significantly improve hair density, reduce hair fall, and decrease scalp visibility in females with Khalitya compared to Nasya alone, with no reported adverse effects.

This study found that BAF200, a subunit of the PBAF chromatin remodeling complex, is crucial for heart development and coronary artery formation in mice, as its absence led to embryonic lethality with severe cardiac defects.